Exploring the link between plasma sphingolipids and radiotherapy effectiveness in liver cancer
Correlation Between Plasma Sphingolipid Metabolites and the Efficacy of Radiotherapy in Hepatocellular Carcinoma
This study is trying to see if the levels of certain fats in the blood can help predict how well radiotherapy works for people with liver cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 260 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Nanfang Hospital, Southern Medical University Academic / other |
| Drugs / interventions | Radiation |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT06864221 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the relationship between plasma sphingolipid levels and the efficacy of radiotherapy in patients with hepatocellular carcinoma. Utilizing advanced LC-MS/MS technology, the study aims to analyze the qualitative and quantitative aspects of sphingolipids in the plasma of liver cancer patients undergoing radiotherapy. By collecting clinical data related to patient prognosis, the research seeks to establish the significance of these metabolites as predictive biomarkers for treatment outcomes, potentially enhancing the effectiveness of radiotherapy in liver cancer management.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 to 80 years with a clinical diagnosis of primary liver cancer who are scheduled to undergo radiotherapy.
Not a fit: Patients with malignancies from other origins or those with severe uncontrolled comorbidities may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a new biomarker for predicting the effectiveness of radiotherapy in liver cancer patients, leading to more personalized treatment strategies.
How similar studies have performed: While the role of sphingolipid metabolism in radiation sensitivity is an emerging area, this specific approach has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients voluntarily signed the informed consent form. * Aged between 18 and 80 years. * Clinically diagnosed with primary liver cancer according to the latest treatment guidelines. * Determined by the treating physician to require radiotherapy. * Expected survival time of more than 3 months. Exclusion Criteria: * Patients who discontinued radiotherapy or did not complete the planned treatment. * Presence of malignancies from other origins. * Severe metabolic diseases such as uncontrolled diabetes, significant obesity, or fatty liver disease. * Uncontrolled comorbidities, such as severe cardiovascular or pulmonary diseases, that may affect treatment or study outcomes.
Where this trial is running
Guangzhou, Guangdong
- Nanfang Hospital, Southern Medical University — Guangzhou, Guangdong, China (Recruiting)
Study contacts
- Principal investigator: Yiyi Li, PhD — Nanfang Hospital, Southern Medical University
- Study coordinator: Yiyi Li, PhD
- Email: liiyiiyii@163.com
- Phone: +8613828486593
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.